Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To provide Pegaptanib sodium injection to patients with subfoveal choroidal
neovascularization (CNV) secondary to AMD, who are unable to participate in any of the
Sponsor's other clinical studies with this drug for AMD, until such time as the patient's
lesion is considered to have resolved or stabilized in the opinion of the treating
ophthalmologist, or product becomes commercially available.